Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
76 stopped studies mapped to Malignant Oropharyngeal Neoplasm and descendants · 89% state a reason
Over the 76 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT05363709 | BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients | Phase 2 | withdrawn | May 6, 2022 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive… | Phase 2 | terminated | Jan 10, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients…(OPPIDOM) | N/A | terminated | Mar 17, 2021 | Institut de cancérologie Strasbourg Europe | organisationnal reason | Other (stated, no rule matched) |
| NCT06276946 | Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia | N/A | withdrawn | Feb 26, 2024 | UNC Lineberger Comprehensive Cancer Center | Operational reason | Other (stated, no rule matched) |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | — | withdrawn | Apr 12, 2024 | Wake Forest University Health Sciences | PI not moving forward with study at our institution | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | Phase 2 | withdrawn | Nov 8, 2022 | Case Comprehensive Cancer Center | PI left | Investigator |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Early Phase 1 | terminated | Jul 11, 2016 | Wake Forest University Health Sciences | Study closed prior to meeting enrollment goal and funding issues | Enrollment / accrual |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing… | Phase 1 | terminated | Oct 19, 2020 | Hyunseok Kang, MD | Slow Accrual | Enrollment / accrual |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and… | Phase 2 | terminated | Nov 14, 2019 | University of Utah | Insufficient funding | Funding |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05849142 | Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive…(OPC-V) | N/A | withdrawn | May 8, 2023 | University of Miami | MRI Linac contract was not renewed at our institution after Viewray went bankrupt. Therefore we… | Enrollment / accrual |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | Phase 2 | withdrawn | Feb 6, 2018 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA… | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Novartis has chosen to withdraw support for this trial | Other (stated, no rule matched) |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122…(PANTHEoN) | Phase 1 | withdrawn | May 19, 2021 | Jennifer Choe | Funding | Funding |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before… | Phase 1 / Phase 2 | terminated | Aug 7, 2018 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous… | Phase 2 | withdrawn | Sep 10, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03555721 | CytID Analysis of Oral Lesions | — | terminated | Jun 13, 2018 | The University of Texas Health Science Center, Houston | low subject recruitment | Enrollment / accrual |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer… | Phase 2 | terminated | Sep 28, 2016 | National Cancer Institute (NCI) | Low accrual combined with expiration of study drug | Enrollment / accrual |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable… | Phase 2 | terminated | Aug 22, 2017 | M.D. Anderson Cancer Center | Closed the trial for infeasibility due to slow accrual | Enrollment / accrual |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | N/A | terminated | Jul 3, 2013 | Paul W. Read, MD | Study had very specific inclusion/exclusion criteria and difficult to recruit | Enrollment / accrual |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT03713021 | TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers | N/A | terminated | Oct 19, 2018 | Washington University School of Medicine | Equipment unavailable | Other (stated, no rule matched) |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the… | Phase 2 | terminated | Sep 1, 2010 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the…(AGMT_HNO_PN) | Phase 3 | terminated | Sep 11, 2014 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Study stopped due to low recruitment | Enrollment / accrual |
| NCT01883908 | Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With…(GCC1229) | N/A | terminated | Jun 21, 2013 | University of Maryland, Baltimore | The project is terminated due to that fact that the PI has moved to another institution and there… | Other (stated, no rule matched) |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or… | Phase 1 | withdrawn | Jul 2, 2018 | Emory University | funding and drug were withdrawn | Funding |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced… | N/A | withdrawn | Aug 2, 2018 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | Phase 2 | terminated | Mar 11, 2016 | University of Chicago | Study stopped due to poor enrollment. | Enrollment / accrual |
| NCT02388932 | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced… | N/A | terminated | Mar 17, 2015 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01053546 | Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and… | N/A | terminated | Jan 21, 2010 | Wake Forest University Health Sciences | slow accrual | Enrollment / accrual |
| NCT02552550 | Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx | — | terminated | Sep 17, 2015 | Centre Hospitalier Universitaire de Saint Etienne | rate of inclusion too low | Other (stated, no rule matched) |
| NCT02628912 | Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers | — | withdrawn | Dec 11, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02225496 | Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Another trial in the department directly competes for the the same patient population | Other (stated, no rule matched) |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | withdrawn | Nov 24, 2014 | Julie E. Bauman, MD, MPH | not stated | Not stated |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | Phase 2 | terminated | Feb 21, 2014 | Roswell Park Cancer Institute | Study no longer has an active IDE | Other (stated, no rule matched) |
| NCT01767961 | Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With… | N/A | withdrawn | Jan 15, 2013 | Wake Forest University Health Sciences | Unable to secure funding. | Funding |
| NCT00895245 | Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing… | Phase 2 | terminated | May 8, 2009 | University of Washington | Study stopped due to lack of efficacy in first 6 patients | Efficacy / futility |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or… | Phase 2 | terminated | Jul 21, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials